Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities researchers at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for shares of Myriad Genetics in a report released on Monday. Leerink Swann analyst P. Souda anticipates that the company will post earnings per share of $0.20 for the quarter. Leerink Swann has a “Market Perform” rating and a $31.00 price target on the stock. Leerink Swann also issued estimates for Myriad Genetics’ Q2 2018 earnings at $0.26 EPS, Q3 2018 earnings at $0.26 EPS, Q4 2018 earnings at $0.31 EPS, Q1 2019 earnings at $0.26 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.29 EPS, Q4 2019 earnings at $0.30 EPS and FY2019 earnings at $1.13 EPS.

Several other research firms have also weighed in on MYGN. Stephens reiterated an “overweight” rating and issued a $40.00 price objective (up previously from $36.00) on shares of Myriad Genetics in a research note on Friday, September 22nd. Cowen and Company reissued a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a research note on Sunday, September 17th. Jefferies Group LLC restated a “hold” rating and issued a $23.00 price target (up from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. Deutsche Bank AG raised shares of Myriad Genetics from a “sell” rating to a “hold” rating and decreased their price target for the company from $27.86 to $15.00 in a research note on Friday, August 18th. Finally, BidaskClub raised shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $24.20.

WARNING: “Myriad Genetics, Inc. Expected to Post Q1 2018 Earnings of $0.20 Per Share (MYGN)” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at

Shares of Myriad Genetics (NASDAQ:MYGN) traded down 0.35% during midday trading on Tuesday, hitting $36.65. 128,725 shares of the stock traded hands. The firm has a 50-day moving average price of $31.66 and a 200-day moving average price of $24.50. Myriad Genetics has a 52 week low of $15.15 and a 52 week high of $36.99. The stock has a market capitalization of $2.51 billion, a P/E ratio of 114.89 and a beta of 0.27.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.04. The firm had revenue of $200.50 million for the quarter, compared to analyst estimates of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.36 earnings per share.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the transaction, the director now directly owns 52,524 shares in the company, valued at approximately $1,591,477.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Arizona State Retirement System bought a new position in shares of Myriad Genetics during the first quarter valued at about $682,000. Airain ltd bought a new stake in Myriad Genetics in the 2nd quarter worth about $1,097,000. PDT Partners LLC bought a new stake in Myriad Genetics in the 2nd quarter worth about $8,481,000. Bank of New York Mellon Corp grew its position in Myriad Genetics by 131.2% in the 1st quarter. Bank of New York Mellon Corp now owns 918,305 shares of the company’s stock worth $17,632,000 after purchasing an additional 521,146 shares in the last quarter. Finally, Blair William & Co. IL bought a new stake in Myriad Genetics in the 2nd quarter worth about $1,048,000.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.